Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa is under clinical development by Holostem Terapie Avanzate and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, Phase II drugs for Epidermolysis Bullosa does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa overview

Gene therapy is under development for the treatment of junctional epidermolysis bullosa (JEB). It consists of autologous cultured epidermal grafts containing epidermal stem cells genetically modified with the aid of a retroviral vector carrying LAMB-3 cDNA. It is administered through cutaneous route.

For a complete picture of Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.